Radioactive bullet targets Hard-to-Treat breast cancer
NCT ID NCT07081555
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 36 times
Summary
This early-stage trial is testing a new drug called [177Lu]Lu-ABY-271, which delivers a small dose of radiation directly to HER2-positive breast cancer cells. The study will enroll 21 people with advanced or metastatic HER2-positive breast cancer to see if the drug is safe, tolerable, and where it goes in the body. It is a first-in-human study, so the main goals are to check for side effects and find the right dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Akademiska Sjukhuset
RECRUITINGUppsala, SE-751 85, Sweden
-
Karolinska University Hospital
RECRUITINGStockholm, SE-17164, Sweden
-
Sahlgrenska University Hospital
RECRUITINGGothenburg, S-413 45, Sweden
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
a radioactive drug called [177Lu]Lu-ABY-271 that targets HER2-positive cancer cells
What this could lead to
If it works, this could provide a new targeted treatment option for people with HER2-positive metastatic breast cancer that has stopped responding to other therapies.
What could go wrong
This is a very early (Phase 1) trial with only 21 people, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects from radiation exposure.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.